What is Cardea Bio?
Cardea Bio operates at the intersection of semiconductor physics and molecular biology. The company has developed a unique Tech+Bio infrastructure that utilizes proprietary Cardean Transistors—graphene-based components that allow for the real-time monitoring of molecular signals. Unlike traditional silicon-based sensors that rely on static measurements, Cardea's hardware provides a dynamic, interactive live-stream of multi-omic data. This capability is central to their mission of Linking up to Life, providing partners with the tools necessary to translate complex biological interactions into actionable digital insights. By replacing optical measurement techniques with high-resolution electronic sensing, Cardea Bio is redefining the standards for diagnostic and analytical precision in the life sciences sector.
How much funding has Cardea Bio raised?
Cardea Bio has raised a total of $10.4M across 5 funding rounds:
Series A
$1.6M
Debt
$600K
Debt
$550K
Debt
$150K
Other Financing Round
$7.5M
Series A (2015): $1.6M with participation from Serra Ventures
Debt (2016): $600K, investors not publicly disclosed
Debt (2017): $550K, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Other Financing Round (2020): $7.5M backed by Lifespan Investments, Table Mountain Capital, Agilent Technologies, Photon Fund, Serra Ventures, Foothill Ventures, and Taihill Venture
Key Investors in Cardea Bio
Serra Ventures
A venture capital firm specializing in early-stage technology startups with a strong emphasis on the AgTech and Food Tech sectors.
Agilent Technologies
A global leader in life sciences and diagnostics, providing advanced analytical instruments and software to laboratories worldwide.
Foothill Ventures
A venture capital firm focused on supporting high-growth technology companies through strategic investment and operational guidance.
What's next for Cardea Bio?
With the recent infusion of capital, Cardea Bio is well-positioned to accelerate the commercial deployment of its multi-omics platform. The strategic focus will likely shift toward expanding the application of Cardean Transistors across diverse sectors, including pharmaceutical development, clinical diagnostics, and environmental monitoring. As the company scales, the integration of its hardware with advanced software and wetware solutions will be critical to maintaining its competitive edge. Investors are closely watching how Cardea Bio leverages these resources to transition from a technology developer to a foundational infrastructure provider for the global biotech industry, potentially setting a new benchmark for how biological data is captured and analyzed at scale.
See full Cardea Bio company page
